Domain > www.aptose.com

More information on this domain is in AlienVault OTX

Whois

Property	Value
NameServer	NS42.DOMAINCONTROL.COM
Created	2013-12-02 00:00:00
Changed	2014-07-22 00:00:00
Expires	2015-12-02 00:00:00
Registrar	GODADDY.COM, LLC

DNS Resolutions

Date	IP Address
2021-10-21	3.221.176.71 (ClassC)
2022-02-11	3.225.74.242 (ClassC)
2023-06-19	54.204.13.102 (ClassC)
2023-12-15	54.225.202.48 (ClassC)
2026-01-04	54.183.47.117 (ClassC)

HTTP/1.1 200 OKDate: Sun, 04 Jan 2026 11:40:12 GMTServer: ApacheExpires: Thu, 19 Nov 1981 08:52:00 GMTCache-Control: no-store, no-cache, must-revalidate, post-check0, pre-check0Pragma: no-cacheSet-Cookie: major_announcementdeleted; expiresThu, 01-Jan-1970 00:00:01 GMT; Max-Age0Vary: Accept-EncodingTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8

!DOCTYPE html>html langen>    head>            meta charsetutf-8>        meta http-equivx-ua-compatible contentieedge>                        link relalternate typeapplication/rss+xml titleAptose Biosciences Inc. - Recent News hrefhttps://www.aptose.com/news-media/press-releases/rss />                    title>Aptose Biosciences Inc. (APS)/title>                    link relcanonical hrefhttps://www.aptose.com>    meta propertyog:url contenthttps://www.aptose.com>    meta propertyog:site_name contentAptose Biosciences Inc.>    meta propertyog:title contentAptose Biosciences Inc.>    meta propertyog:type contentwebsite>        meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/795/6267/social_image_resized.jpg>    meta nametwitter:card contentsummary_large_image>    meta propertyog:description contentAptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.>    meta namedescription contentAptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.>        meta nameviewport contentinitial-scale1.0, widthdevice-width>                                link relstylesheet typetext/css hrefhttps://cloud.typography.com/6224976/7959812/css/fonts.css />                            link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/css/style.css>                                link relshortcut icon hrefhttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/images/favicons/favicon.ico>        link relapple-touch-icon sizes180x180 hrefhttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/images/favicons/apple-touch-icon.png>        link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/images/favicons/favicon-32x32.png sizes32x32>        link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/images/favicons/favicon-16x16.png sizes16x16>        link relmask-icon hrefhttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/images/favicons/safari-pinned-tab.svg>        meta nametheme-color content#ffffff>              script>    (function(i,s,o,g,r,a,m){iGoogleAnalyticsObjectr;irir||function(){    (ir.qir.q||).push(arguments)},ir.l1*new Date();as.createElement(o),    ms.getElementsByTagName(o)0;a.async1;a.srcg;m.parentNode.insertBefore(a,m)    })(window,document,script,https://www.google-analytics.com/analytics.js,ga);        ga(create, UA-145047474-1, aptose.com);        (function() {        var opts  {};        var prefix  /investors;        if (location.hostname.indexOf(stockpr.com)  0) {            opts.cookiePath  location.pathname.substring(0, location.pathname.indexOf(/, 1) + 1)            opts.page  prefix + location.pathname.substring(location.pathname.indexOf(/, 1));        } else if (location.hostname.match(/^ir\./)) {            opts.page  prefix + location.pathname;        }        ga(send, pageview, opts);    })();        /**        * Function that tracks a click on an outbound link in Analytics.        * This function takes a valid URL string as an argument, and uses that URL string        * as the event label. Setting the transport method to beacon lets the hit be sent        * using navigator.sendBeacon in browser that support it.        */        var trackOutboundLink  function(url,category) {            if (!category) category  outbound;           ga(send, event, category, click, url, {             transport: beacon           });        }                 window.onload  function() {            // Add outbound link tracking in GA            jq(a).not(.fancybox).each(function(){                var href  jq(this).attr(href);                if (typeof href  undefined) return;                if (href.indexOf(http) > 0                     && ( href.indexOf(website_base_url)  0 && href.indexOf(ir_base_url)  0 && href.indexOf(eqcdn)  0 && href.indexOf(amazonaws)  0)) {                    jq(this).attr(onclick, trackOutboundLink( + href + ));                    }else {                    // Its not an outbound link, but if its a link to a file, we want to track that.                    if (href.match(/(\.pdf|\.jpg|\.png|\.gif|\.ppt|\.jpeg|\.mp3|\.mp4|\.wav|\.docx|\.doc|\.xsl|\.cslx)/g)) {                        jq(this).attr(onclick, trackOutboundLink( + href + , documents-and-files));                    }                }            });        };/script>    /head>body classpg-1 page-type-home pg-overview-overview home>	div classgeneral-wrapper>    	header classaffixed>        div classcontainer>		h1 classlogo>	        a href/>	            span classsr-only>Aptose Biosciences Inc./span>	            svg xmlnshttp://www.w3.org/2000/svg width250 height71 viewBox0 0 250 71>                    g fillnone fill-ruleevenodd>                        path fill#696157 dM165.623 17.257c-.583-.908-1.56-1.645-2.626-2.292-.668-.316-1.65-.54-2.426.339-1.055 1.192-.495 2.782.067 3.542.08.11.161.2.237.272.01.01.004.022.012.032.422.521.821 1.068 1.174 1.668 1.172 2.001 2.45 5.125 2.008 7.573-.226 1.242-.896 2.312-2.25 2.97-2.186 1.06-1.764 2.13-2.829 4.089-2.756 5.076-7.904 8.139-13.452 5.642-4.952-2.228-7.858-7.439-7.858-12.804v-.097c0-1.818.016-4.895.894-6.521 1.058-1.958 3.74-2.687 5.315-4.129 3.637-3.33 8.402-3.797 12.402-1.985v-.003l.028.017c.098.045.193.097.291.145.536.225 1.625.453 2.265-1.025.52-1.205-.154-1.928-.778-2.32a17.552 17.552 0 0 0-7.19-1.535c-2.72 0-6.34.095-8.945.908-2.667.833-4.55 2.303-5.595 4.876-.337.834-.716 1.65-1.092 2.466-.088.373-.118 1.037.374 1.902.594 1.047 1.289 1.97.668 3.69-.62 1.72-2.477 1.819-2.477 1.819s-.531.125-.572 1.16c.012.253.018.506.04.762v.003c.36 4.042 2.004 8.293 4.266 11.122 3.223 4.024 8.134 6.197 13.238 6.197 3.481 0 6.57-.963 9.146-2.581.219-.101.424-.207.605-.31.376-.214.676-.318 1.13-.325 1.29-.02 2.466.787 3.75.37 1.447-.468 1.992-1.495 2.038-3.004.026-.774-.242-1.38-.67-1.99-.355-.498-.66-.856-.593-1.511.04-.37.212-.739.354-1.11a18.22 18.22 0 0 0 1.396-6.991v-.097c0-2.197-.68-3.263-1.366-5.135-.685-1.876.158-4.023-.98-5.799zm46.05 47.354l-1.202-.715c-.539-.317-.93-.62-1.173-.91-.243-.289-.365-.598-.365-.93 0-.372.165-.678.495-.917.33-.24.753-.358 1.266-.358.912 0 1.764.383 2.555 1.148v-1.795a4.405 4.405 0 0 0-2.523-.777c-.96 0-1.74.271-2.34.815-.6.542-.9 1.25-.9 2.119 0 .58.158 1.094.476 1.539.317.445.85.898 1.6 1.358l1.195.731c.965.603 1.447 1.241 1.447 1.914a1.3 1.3 0 0 1-.492 1.036c-.328.276-.738.414-1.23.414-1.117 0-2.1-.541-2.948-1.623v2.008c.89.672 1.879 1.007 2.963 1.007.944 0 1.71-.277 2.3-.83.59-.554.884-1.273.884-2.16 0-1.244-.67-2.269-2.008-3.074zm-18.488 1.081h4.498v-1.416h-4.498v-3.37h4.655V59.5h-6.228v11.034h6.377v-1.408h-4.804v-3.433zm-18.918 2.357c-.817-.78-1.226-1.777-1.226-2.99 0-1.201.415-2.202 1.247-3 .83-.8 1.875-1.2 3.133-1.2 1.226 0 2.481.37 3.766 1.108v-1.701c-1.41-.606-2.692-.91-3.845-.91-1.673 0-3.078.549-4.219 1.646-1.14 1.097-1.71 2.449-1.71 4.057 0 1.012.25 1.954.747 2.824a5.465 5.465 0 0 0 2.029 2.049c.854.495 1.895.743 3.122.743 1.509 0 2.84-.317 3.993-.949v-1.74c-1.268.822-2.568 1.234-3.9 1.234-1.273 0-2.318-.39-3.137-1.17zm-14.648.032l-7.406-8.582h-1.274v11.05h1.478v-8.51l7.344 8.51h1.352v-11.05h-1.494v8.582zm-23.579-2.389h4.498v-1.416h-4.498v-3.37h4.655V59.5h-6.227v11.034h6.377v-1.408h-4.805v-3.433zm-13.956 4.857h1.573v-11.05h-1.573v11.05zm-17.36-2.5c-.818-.78-1.227-1.777-1.227-2.99 0-1.201.416-2.202 1.247-3 .83-.8 1.875-1.2 3.133-1.2 1.226 0 2.482.37 3.766 1.108v-1.701c-1.41-.606-2.691-.91-3.845-.91-1.671 0-3.078.549-4.218 1.646-1.14 1.097-1.71 2.449-1.71 4.057 0 1.012.25 1.954.747 2.824a5.467 5.467 0 0 0 2.029 2.049c.854.495 1.895.743 3.121.743 1.51 0 2.841-.317 3.994-.949v-1.74c-1.268.822-2.568 1.234-3.9 1.234-1.273 0-2.32-.39-3.137-1.17zm-14.543-3.438l-1.2-.715c-.54-.317-.93-.62-1.174-.91-.243-.289-.364-.598-.364-.93 0-.372.164-.678.494-.917.33-.24.753-.358 1.266-.358.912 0 1.765.383 2.556 1.148v-1.795a4.405 4.405 0 0 0-2.524-.777c-.96 0-1.739.271-2.34.815-.6.542-.899 1.25-.899 2.119 0 .58.158 1.094.475 1.539.317.445.85.898 1.6 1.358l1.195.731c.965.603 1.447 1.241 1.447 1.914 0 .415-.164.76-.491 1.036-.328.276-.738.414-1.23.414-1.117 0-2.1-.541-2.95-1.623v2.008c.892.672 1.88 1.007 2.965 1.007.943 0 1.71-.277 2.3-.83.59-.554.884-1.273.884-2.16 0-1.244-.67-2.269-2.01-3.074zM73.39 68.01c-.82.807-1.842 1.21-3.067 1.21-1.22 0-2.236-.395-3.048-1.186-.812-.79-1.217-1.782-1.217-2.974 0-1.229.404-2.238 1.213-3.029.81-.79 1.842-1.186 3.1-1.186 1.193 0 2.2.4 3.02 1.198.819.798 1.229 1.784 1.229 2.954 0 1.203-.41 2.207-1.23 3.013zm-3.083-8.668c-1.697 0-3.1.54-4.211 1.62-1.11 1.082-1.666 2.448-1.666 4.098 0 1.609.551 2.947 1.654 4.015 1.102 1.067 2.482 1.601 4.137 1.601 1.734 0 3.17-.534 4.31-1.601 1.139-1.068 1.709-2.417 1.709-4.047 0-1.629-.565-2.984-1.694-4.065-1.129-1.081-2.542-1.621-4.239-1.621zM53.177 70.549h1.573v-11.05h-1.573v11.05zM41.332 68.31a1.666 1.666 0 0 1-.738.63c-.307.134-.89.2-1.75.2h-1.549v-3.503h1.47c.781 0 1.352.069 1.714.205.362.138.641.346.838.625.196.28.295.588.295.926 0 .327-.094.632-.28.917zm-4.037-7.403h1.352c1.342 0 2.013.53 2.013 1.59 0 .511-.177.928-.53 1.25-.354.321-.95.482-1.789.482h-1.046v-3.322zm3.318 3.797c1.116-.47 1.675-1.247 1.675-2.334 0-.564-.134-1.06-.4-1.491-.269-.43-.657-.767-1.165-1.012-.509-.245-1.216-.368-2.123-.368h-2.878v11.05h3.72c.838 0 1.537-.14 2.095-.42.558-.279.981-.64 1.27-1.083a2.71 2.71 0 0 0 .432-1.511c0-.712-.237-1.324-.711-1.835-.475-.511-1.113-.844-1.915-.996z/>                        path fill#9F1C30 dM131.69 24.399c1.075-.316 1.486-1.024 1.53-2.069.064-1.414-.595-1.212-1.558-1.718 0 0-.205-.143-.388-.121-2.924.332-2.645 4.807.416 3.908zm32.248-18.29s-.341-.255-.648-.217c-4.874.593-4.408 8.57.694 6.967 1.793-.563 2.478-1.825 2.553-3.688.1-2.519-.992-2.16-2.599-3.061zm-3.187-2.197c1.076-.316 1.486-1.024 1.53-2.069.063-1.414-.594-1.212-1.557-1.718 0 0-.205-.143-.39-.123-2.923.334-2.643 4.807.417 3.91zm-26.35 39.26s-.344-.256-.65-.22c-4.873.594-4.406 8.57.696 6.97 1.793-.564 2.477-1.826 2.551-3.69.102-2.517-.99-2.158-2.597-3.06zm115.114-24.155v-3.79h-24.219v28.015h24.219v-3.79h-19.632v-8.775h16.283v-3.79h-16.283v-7.87h19.632zm-54.307 8.528l-6.054-1.4c-2.845-.7-4.312-1.648-4.312-3.584 0-2.102 2.064-3.75 6.926-3.75 3.486 0 7.522 1.03 9.724 2.225l1.376-3.955c-2.34-1.112-6.56-2.225-10.917-2.225-8.256 0-12.062 3.667-12.062 8.076 0 3.666 2.567 6.18 7.797 7.291l5.596 1.237c3.806.823 5.412 1.936 5.412 3.913 0 2.76-3.12 4.327-7.66 4.327-4.082 0-7.797-1.402-9.907-2.596l-1.147 4.119c1.973 1.03 6.467 2.431 10.963 2.431 7.384 0 12.704-3.419 12.704-8.61 0-3.955-2.935-6.18-8.44-7.499zM93.935 19.017h11.191v24.225h4.77V19.017h10.642v-3.79H93.935v3.79zm-29.308 12.32h-8.67v-12.36h8.67c3.806 0 6.88 2.1 6.88 6.262 0 3.79-3.074 6.097-6.88 6.097zm.733-16.11H51.187v28.015h4.77v-8.157h9.403c5.963 0 11.1-3.667 11.1-9.846 0-6.84-5.137-10.012-11.1-10.012zM8.99 33.807l6.697-14.295 6.33 14.296H8.99zm3.945-18.58L0 43.242h4.862l2.844-6.18h15.549l2.752 6.18h4.862L18.485 15.227h-5.55z/>                    /g>                /svg>           /a>		/h1>        a classvisible-xs visible-sm mobile-nav-trigger idshowRight>            div classmeat>/div>            div classmeat>/div>            div classmeat>/div>        /a>		nav classcbp-spmenu cbp-spmenu-vertical cbp-spmenu-right main-nav idmobile-nav>			ul classmain-menu>    li classsr-only>a href/>Home/a>/li>        li classhas-children data-submenu-idsubmenu-about>        a href/about >About/a>                    ul idsubmenu-about>                                    li class>                        a href/about >Overview/a>                    /li>                                    li class>                        a href/about/management-team >Management Team/a>                    /li>                                    li class>                        a href/about/board-of-directors >Board of Directors/a>                    /li>                                    li class>                        a href/about/scientific-advisory-board >Scientific Advisory Board/a>                    /li>                            /ul>            /li>        li classhas-children data-submenu-idsubmenu-product-pipeline>        a href/product-pipeline >Product Pipeline/a>                    ul idsubmenu-product-pipeline>                                    li class>                        a href/product-pipeline >Overview/a>                    /li>                                    li class>                        a href/product-pipeline/hm43239 >Tuspetinib for AML/a>                    /li>                                    li class>                        a href/product-pipeline/luxeptinib-for-b-cell >Luxeptinib for B-cell Tumors/a>                    /li>                                    li class>                        a href/product-pipeline/luxeptinib-for-aml >Luxeptinib for Myeloid Tumors/a>                    /li>                                    li class>                        a href/product-pipeline/posters-presentations >Posters & Presentations/a>                    /li>                            /ul>            /li>        li classhas-children data-submenu-idsubmenu-clinical-trials>        a href/clinical-trials >Clinical Trials/a>                    ul idsubmenu-clinical-trials>                                    li class>                        a href/clinical-trials >Overview/a>                    /li>                                    li class>                        a href/clinical-trials/luxeptinib-for-b-cell >Luxeptinib for CLL & NHL/a>                    /li>                                    li class>                        a href/clinical-trials/luxeptinib-for-aml >Luxeptinib for AML/a>                    /li>                                    li class>                        a href/clinical-trials/tuspetinib >Tuspetinib for AML/a>                    /li>                                    li class>                        a href/clinical-trials/expanded-access >Expanded Access/a>                    /li>                            /ul>            /li>        li classhas-children data-submenu-idsubmenu-news-media>        a href/news-media >News/a>                    ul idsubmenu-news-media>                                    li class>                        a href/news-media/press-releases >Press Releases/a>                    /li>                                    li class>                        a href/news-media/presentations >Presentations/a>                    /li>                                    li class>                        a href/news-media/events >Events/a>                    /li>                            /ul>            /li>        li classhas-children data-submenu-idsubmenu-investors>        a href/investors >Investors/a>                    ul idsubmenu-investors>                                    li class>                        a href/investors >Overview/a>                    /li>                                    li classhas-children>                        a href/investors/news-events >News & Events/a>                    /li>                                    li classhas-children>                        a href/investors/company-information >Company Info/a>                    /li>                                    li classhas-children>                        a href/investors/financial-information >Financial Info/a>                    /li>                                    li classhas-children>                        a href/investors/stock-data >Stock Data/a>                    /li>                                    li classhas-children>                        a href/investors/sec-filings >SEC Filings/a>                    /li>                                    li class>                        a hrefhttps://www.sedarplus.ca/csa-party/records/profile.html?id081f2f9cc38da9160a57388cc6761bdb target_blank>SEDAR/a>                    /li>                                    li classhas-children>                        a href/investors/corporate-governance > Governance/a>                    /li>                            /ul>            /li>        li classhas-children data-submenu-idsubmenu-join-us>        a href/join-us >Join Us/a>                    ul idsubmenu-join-us>                                    li class>                        a href/join-us/values-culture >Values & Culture/a>                    /li>                                    li class>                        a href/join-us/perks-benefits >Perks & Benefits/a>                    /li>                                    li class>                        a href/join-us/explore-careers >Explore Careers/a>                    /li>                            /ul>            /li>        li class data-submenu-idsubmenu-contact>        a href/contact >Contact/a>            /li>        /ul>		/nav>    /div>/header>div classpage-banner overlay dark home-hero stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/781/5990/image.jpg);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;>    div classvertical-element>    	div classcontainer>    	    div classrow>    	        div classcol-sm-6>    	            div classtext>    	                                    h2>Precision Oncology for Therapies of Tomorrow/h2>                                            p>Aptose Biosciences is a science-driven clinical-stage biotechnology company committed to precision medicines addressing the unmet clinical needs in oncology, with an initial focus on hematology. The Companys small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities./p>div classinline-btns>a classbtn href/about>Who We Are/a> a href/clinical-trials classbtn>View Our Clinical Trials/a>/div>                                		/div>    	        /div>    	    /div>        /div>    /div>/div>div classmodule module-hover-blocks neutral-bg idrow-6602>	div classcontainer>		div classrow>            div classcol-lg-5 col-md-6>                div classtext>                                    h2>Broad Applicability Across the Hematology Spectrum/h2>                                                    p>span>Our /span>span>drug candidates /span>have been designed to provide span>safe /span>single agent efficacyspan> in multiple /span>span>adjacent /span>span>indications/span>, as well as enhance the span>efficacy /span>of other anti-cancer therapies and regimens without overlapping toxicities./p>                                    a href/product-pipeline classbtn>View Product Pipeline/a>                                /div>            /div>            div classcol-md-6 col-lg-offset-1>                div classblocks-wrapper>                                    div classhover-block>                        span classproduct>Tuspetinib (formerly HM43239): Myeloid Kinase Inhibitor (MKI) for AML /span>                        div classhover-content>                            div classheader>                                span classproduct>Tuspetinib (formerly HM43239): Myeloid Kinase Inhibitor (MKI) for AML /span>                            /div>                            div classdescription>                                p>Tuspetinib is a potent oral inhibitor of key kinases operative in myeloid malignancies, including SYK, FLT3, JAK, c-KIT(mut), and others./p>                                                            a href/product-pipeline/hm43239 classblock-link>View Candidate/a>                                                        /div>                        /div>                    /div>                                    div classhover-block>                        span classproduct>Luxeptinib: Lymphoid Kinome Inhibitor (LKI) for B-NHL/span>                        div classhover-content>                            div classheader>                                span classproduct>Luxeptinib: Lymphoid Kinome Inhibitor (LKI) for B-NHL/span>                            /div>                            div classdescription>                                p>Luxeptinib is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies./p>                                                            a href/product-pipeline/luxeptinib-for-b-cell classblock-link>View Candidate/a>                                                        /div>                        /div>                    /div>                                    div classhover-block>                        span classproduct>Luxeptinib: Myeloid Kinome Inhibitor (MKI) for AML/MDS/span>                        div classhover-content>                            div classheader>                                span classproduct>Luxeptinib: Myeloid Kinome Inhibitor (MKI) for AML/MDS/span>                            /div>                            div classdescription>                                p>Luxeptinib potently inhibits wildtype and all mutant forms of FLT3 which are an oncogenic drivers in AML and MDS, as well as other oncogenic rescue pathways operative in myeloid malignancies./p>                                                            a href/product-pipeline/luxeptinib-for-aml classblock-link>View Candidate/a>                                                        /div>                        /div>                    /div>                                /div>            /div>		/div>					/div>/div>div classmodule module-content-image idrow-6603>    div classimages-column data-mh>        div classfeatured-image>            img srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/835/6651/image.jpg altfeatured image>        /div>            div classextra-images>                    img srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/835/6652/image.jpg alt>                    img srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/835/6653/image.jpg alt>                /div>        /div>	div classcontainer>		div classrow>			div classcol-lg-5 col-sm-6>			    div classvertical-align data-mh>			        div classwrapper>                        div classtext>                                                    h2>Our Clinical Trials in Hematologic Malignancies/h2>                                                                            p>Currently, we have three ongoing clinical trials with our investigational drug candidates:/p>h3>Tuspetinib: Phase 1/2/h3>p>Tuspetinib is in a Phase 1/2 clinical trial for the treatment of patients with relapsed or refractory AML/p>h3>Luxeptinib: Phase 1a/b/h3>p>Luxeptinib is in a Phase 1a/b clinical trial for the treatment of patients with B-cell malignancies, including CLL and NHL, who have failed or are intolerant to the standard treatments available./p>h3>Luxeptinib: Phase 1a/b/h3>p>Luxeptinib is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML and high risk MDS./p>                                                    a href/clinical-trials classbtn>View Clinical Trials/a>                                                /div>                    /div>                /div>			/div>		/div>					/div>/div>div classmodule module-latest-news-slider wide-bg no-padding-top  >    div classwide-bg-box stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/830/6604/background_image.png);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;>/div>    div classcontainer>        h2>Latest News/h2>        div classhidden-sm hidden-xs>            div classslider-nav>/div>        /div>                div classvisible-sm visible-xs>            div classmobile-news center>                div classnews-block>                    a hrefhttps://www.aptose.com/news-media/press-releases/detail/339/aptose-biosciences-announces-rescheduling-of-special>                        div classtext>                            time classdate datetime2025-12-19T17:05:00>Dec 19, 2025 • 5:05 PM EST/time>                            p>Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC/p>                        /div>                    /a>                /div>!-- .news-block-->            /div>        /div>                div classnews-slider hidden-xs hidden-sm>                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/339/aptose-biosciences-announces-rescheduling-of-special>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-12-19T17:05:00>Dec 19, 2025 • 5:05 PM EST/time>                        p>Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/338/aptoses-tuspetinib-triple-drug-therapy-featured-at-the>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-12-06T08:00:00>Dec 6, 2025 • 8:00 AM EST/time>                        p>Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/337/aptose-biosciences-announces-arrangement-agreement-for>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-11-19T01:22:00>Nov 19, 2025 • 1:22 AM EST/time>                        p>Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/336/aptose-reports-third-quarter-2025-results>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-11-13T17:00:00>Nov 13, 2025 • 5:00 PM EST/time>                        p>Aptose Reports Third Quarter 2025 Results/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/335/aptose-tuspetinib-clinical-data-from-ongoing-tuscany-trial>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-11-03T09:00:00>Nov 3, 2025 • 9:00 AM EST/time>                        p>Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/334/aptoses-tuspetinib-exceeds-expectations-when-combined>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-10-16T07:30:00>Oct 16, 2025 • 7:30 AM EDT/time>                        p>Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/333/aptose-and-hanmi-pharmaceutical-extend-loan-agreement-to>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-09-22T07:30:00>Sep 22, 2025 • 7:30 AM EDT/time>                        p>Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/332/aptose-biosciences-announces-results-of-reconvened-annual>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-08-22T17:01:00>Aug 22, 2025 • 5:01 PM EDT/time>                        p>Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor/p>                    /div>                /a>            /div>!--end cell-->                    div classnews-block>                a hrefhttps://www.aptose.com/news-media/press-releases/detail/331/aptose-reports-early-data-demonstrating-tuspetinib-improves>                    div classtext data-mhnews-text-box>                        time classdate datetime2025-08-18T07:30:00>Aug 18, 2025 • 7:30 AM EDT/time>                        p>Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial/p>                    /div>                /a>            /div>!--end cell-->                /div>        /div>/div>div classsubscribe subscribe-module >    div classsubscribe-bg overlay gradient-overlay stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/db/830/6605/background_image.jpg);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;>        div classsubscribe-wrapper>            div classcontainer>                div classtext>                                    h2>Email Alerts/h2>                    p>Stay informed and receive company updates straight to your inbox./p>                                    a href/investors/news-events/email-alerts classbtn>Learn More/a>                                /div>            /div>        /div>    /div>/div>div classmodule module-stock-info-right-data>    div classir-quote-box>        div classstock-info >            div classcontainer>                div classmodule-content text>                    h2>Stock Snapshot/h2>                            		        		/div>        		div classtab-header>                    ul classnav roletablist>                                            li rolepresentation classactive>a href#tab-APS aria-controlstab-APS roletab data-toggletab>TSX/a>/li>                                                            /ul>                /div>                div classtab-content data-nameqmod>                                    div roletabpanel classtab-pane active idtab-APS>                        div data-nameqmod classstock-info quote-box qtool data-qmod-tooldetailedquotetab data-qmod-params{"lang":"en","showLogo":false,"lowHigh":false,"symbol":"APS:CA"}>    span classloader>/span>    script typetext/template>    div classrow>        div classcol-md-4>            span classsymbol>TSX: APS/span>            h4>Aptose Biosciences Inc./h4>            span classdate>{data.pricedata.lasttradedatetime | momentjs true LLL tLang} {data.tz | asTimezone tLang}/time>/span>        /div>        div classcol-md-8 stock-info-column>            div classrow>                div classcol-sm-3>                    div classstock-section price>                        span classvalue>${data.pricedata.last | asQHLast tLang }/span>                        span classvalue-title>{tplLang.price| toLang tLang}/span>                    /div>                /div>                div classcol-sm-6>                    div classstock-section change>                        span classvalue>        			        span rv-qmodchangedata.pricedata.change classqmod-change>        			        span classnumber>{data.pricedata.change | asQHLast tLang }/span>        			        span classpercent> ({data.pricedata.changepercent | numeraljs 0.00 0.00 | postFix %})/span>        			        /span>        			    /span>                        span classvalue-title>{tplLang.change| toLang tLang}/span>                    /div>                /div>                div classcol-sm-3>                    div classstock-section volume>                        span classvalue>{data.pricedata.sharevolume | numeraljs 0.00a}/span>                        span classvalue-title>{tplLang.volume| toLang tLang}/span>                    /div>                /div>            /div>        /div>    /div>/script>/div>!--end stock-info-->                        div classqm-range-row row>                            div classcol-md-8 col-md-offset-4>                            div data-nameqmod classstock-info quote-box quote-box-range-row qtool data-qmod-tooldayyearrange data-qmod-params{"lang":"en","rangePctWidth":65,"symbol":"APS:CA"}>    span classloader>/span>    script typetext/template>    div classqmod-dayyearrange qmod-ui-tool>        div classqmod-range>            div classqmod-range-container>                div classqmod-range-row qmod-range-day>                    div rv-style-widthscope.data.labelPct classqmod-range-segment qmod-range-label>                        div classqmod-range-element>Day Range/div>                    /div>                    div rv-style-widthscope.data.rangePct classqmod-range-segment qmod-range-data>                        div rv-style-flex-basisscope.data.underPct classqmod-range-segment qmod-range-under>                            div rv-showscope.data.dayLow | nq 0 classqmod-range-element>{scope.data.dayLow | asQHLast tLang}/div>                        /div>                        div rv-style-flex-basisscope.data.midPct classqmod-range-segment qmod-range-mid>/div>                        div rv-style-flex-basisscope.data.overPct classqmod-range-segment qmod-range-over>                            div rv-showscope.data.dayHigh | nq 0 classqmod-range-element>{scope.data.dayHigh | asQHLast tLang}/div>                        /div>                    /div>                /div>                div classqmod-range-row qmod-range-graphic>                    div rv-style-widthscope.data.labelPct classqmod-range-segment qmod-range-label>/div>                    div rv-style-widthscope.data.rangePct classqmod-range-segment qmod-range-data>                        div rv-style-widthscope.data.underPct classqmod-range-segment qmod-range-under>/div>                        div rv-style-widthscope.data.midPct classqmod-range-segment qmod-range-mid>/div>                        div rv-style-widthscope.data.overPct classqmod-range-segment qmod-range-over>/div>                    /div>                /div>                div classqmod-range-row qmod-range-year>                    div rv-style-widthscope.data.labelPct classqmod-range-segment qmod-range-label>                        div classqmod-range-element>52 Week Range/div>                    /div>                    div rv-style-widthscope.data.rangePct classqmod-range-segment qmod-range-data>                        div rv-showscope.data.week52Low | nq 0 classqmod-range-element>{scope.data.week52Low | asQHLast tLang}/div>                        div rv-showscope.data.week52High | nq 0 classqmod-range-element>{scope.data.week52High | asQHLast tLang}/div>                    /div>                /div>            /div>        /div>    /div>/script>/div>!--end stock-info-->                            /div>                        /div>                    /div>                                    /div>                            div classhome-links-module>        	                        a classbtn href/investors>View Investor Relations/a>                                                /div>                        /div>        /div>    /div>    /div>footer classhas-qmod>    div classfooter-main>    	div classcontainer>    		div classcopyright>    			© 2025 a href/>Aptose Biosciences Inc./a> All Rights Reserved.    		/div>    		div classfooter-links>    			    a href/privacy-policy>Privacy Policy/a>    a href/clinical-trials-policy>Clinical Trials Policy/a>    a href/disclaimer>Disclaimer/a>    a href/sitemap>Sitemap/a>    			                a idklaroPrefs href# rolebutton>Manage Cookie Preferences/a>                    		/div>    	/div>	/div>	div classqmod-attribution>    div classcontainer>        div classq-mod-attribution disclaimer>            div classrow>                div classcol-md-10 col-md-offset-1 center>                     p>                    Market Data copyright © 2026 a hrefhttp://www.quotemedia.com target_blank relnofollow>QuoteMedia/a>. Data delayed 15 minutes unless otherwise indicated (view a hrefhttp://www.quotemedia.com/legal/tos/#times target_blank relnofollow >delay times/a> for all exchanges). span classqmf-rt>RT/span>Real-Time, span classqmf-non-rt>EOD/span>End of Day, span classqmf-non-rt>PD/span>Previous Day. Market Data powered by a hrefhttp://www.quotemedia.com target_blank relnofollow >QuoteMedia/a>. a hrefhttp://www.quotemedia.com/legal/tos/ target_blank relnofollow >Terms of Use/a>.                    /p>                /div>            /div>        /div>    /div>/div>/footer>    script>        var asset_url  https://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose;        var website_base_url  https://www.aptose.com;        var ir_base_url  /investors;        var isQmod  true;    /script>script srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/js/aside/klaro-cookie-consent/_js/all.js data-configklaroConfig defer>/script>script srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/js/_js/all.js>/script>    script srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/js/aside/modules/row-media-news-slider/_js/all.js>/script>    script>        jq(.news-slider).slick({          infinite: false,          dots: true,          variableWidth: true,          arrows: true,          prevArrow: div classprev prev-arrow>svg xmlnshttp://www.w3.org/2000/svg width11 height20 viewBox0 0 11 20>path fill#999 fill-rulenonzero dM9.733 19.161L0 9.581 9.733 0l.912.898-8.82 8.683 8.82 8.682z/>/svg>/div>,          nextArrow: div classnext next-arrow>svg xmlnshttp://www.w3.org/2000/svg width11 height19 viewBox0 0 11 19>path fill#999 fill-rulenonzero dM.932 0L0 .88l9.007 8.508L0 17.896l.932.88 9.939-9.388z/>/svg>/div>,          appendArrows: .slider-nav,          appendDots: .slider-nav,           slidesToShow: 3,          slidesToScroll: 3,          responsive:             {              breakpoint: 1199,              settings: {                slidesToShow: 3,                variableWidth: true,                slidesToScroll: 3              }            },            {              breakpoint: 991,              settings: {                slidesToShow: 2,                variableWidth: false,                slidesToScroll: 1              }            },            {              breakpoint: 767,              settings: {                slidesToShow: 1,                variableWidth: false,                slidesToScroll: 1              }            }                  });    /script>            script typetext/plain                idqmod                data-typeapplication/javascript                data-nameqmod                data-srchttps://qmod.quotemedia.com/js/qmodLoader.js                data-qmod-wmid93303 data-qmod-envapp data-qmod-versionv1.3.0            >/script>script srchttps://d1io3yog0oux5.cloudfront.net/_169a10b1013c323a84b59594130cbbd6/aptose/files/theme/js/aside/_js/browser-check.min.js async>/script>    	    /div>!-- //general-wrapper -->/body>

Subdomains

Date	Domain	IP
ir.aptose.com	2024-08-25	3.101.49.128
www.aptose.com	2026-01-04	54.183.47.117

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > www.aptose.com

Is this malicious?

Whois

DNS Resolutions

Port 443

Subdomains